Author pages are created from data sourced from our academic publisher partnerships and public sources.
Targeting multidrug resistance in cancer
- G. Szakács, Jill K. Paterson, J. Ludwig, Catherine L. Booth-Genthe, M. Gottesman
- Biology, Medicine
- Nature Reviews Drug Discovery
- 1 March 2006
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this… Expand
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the… Expand
Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future
- J. Ludwig
- Current opinion in oncology
- 1 July 2008
Purpose of review As the second most common bone malignancy in children and adolescents, Ewing sarcoma family tumors represent almost 3% of pediatric cancers. Multidisciplinary management of patients… Expand
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
ATP-binding cassette (ABC) proteins include the best known mediators of resistance to anticancer drugs. In particular, ABCB1 [MDR1/P-glycoprotein (P-gp)] extrudes many types of drugs from cancer… Expand
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
BACKGROUND Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for… Expand
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor
Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic… Expand
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Purpose: Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R). Experimental Design: Patients received… Expand
Universal marker and detection tool for human sarcoma circulating tumor cells.
To date, no specific marker exists for the detection of circulating tumor cells (CTC) from different types of sarcomas, though tools are available for detection of CTCs in peripheral blood of… Expand
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor.
- R. Pandurengan, A. Dumont, +7 authors J. Trent
- Annals of oncology : official journal of the…
- 1 October 2010
BACKGROUND We sought to investigate the characteristics and survival rate of patients with gastrointestinal stromal tumor (GIST) associated with other primary malignancies. PATIENTS AND METHODS A… Expand
Complete Cytoreduction and HIPEC Improves Survival in Desmoplastic Small Round Cell Tumor
BackgroundDesmoplastic small round cell tumor (DSRCT) is a rare tumor of adolescents and young adults. Less than 100 cases per year are reported in North America. Extensive peritoneal metastases are… Expand